Marwan Noel Sabbagh is board certified neurologist and geriatric neurologist and is considered one of the leading experts in Alzheimer’s and dementia. Dr Sabbagh has dedicated his career to finding a cure for Alzheimer’s and other age-related neurodegenerative diseases. Dr Sabbagh is a leading investigator for many prominent national Alzheimer’s prevention and treatment trials. Dr Sabbagh is on the editorial board for Journal of Alzheimer's Disease and Alzheimer’s and Dementia TRCI. He is editor in chief of Neurology and Therapy. He has authored and co-authored almost 400 medical and scientific articles on Alzheimer’s research. Dr Sabbagh earned his undergraduate degree from the University of California, Berkeley and his medical degree from the University of Arizona in Tucson. He received his residency training in neurology at Baylor College of Medicine, Houston, Texas, and completed his fellowship in geriatric neurology and dementia at the University of California, San Diego School of Medicine, where he served on the faculty as assistant professor. Before rejoining the faculty of the Barrow Neurological Institute, he was the Camille and Larry Ruvo Endowed Chair for Brain Health and Director of the Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas. Prior to that, he was the director of the Banner Sun Health Research Institute.

Dr. Sadowsky is currently the Director of Research at Palm Beach Neurology, Premiere Research Institute, in West Palm Beach, Florida. He is also Clinical Professor, Division of Neurology, Nova Southeastern University, Fort Lauderdale, Florida. His research focuses on clinical trials to test new drug candidates for the management of Alzheimer’s Disease (AD). He is also interested in novel biomarkers to aid in the early diagnosis of AD and was one of the first to study and report on the safety and efficacy of the Sapphire System when used to detect beta-amyloid in the human lens. He is a Fellow of the American Academy of Neurology, a board member of the Southeast Florida Alzheimer’s Association, and a member of the scientific review board for the Alzheimer’s Drug Discovery Foundation. He has been selected by Best Doctors in America for 12 consecutive years. Dr. Sadowsky received his medical degree from Cornell University’s Weill Medical College and completed an internship and residency in internal medicine and a residency in neurology at Dartmouth-Hitchcock Medical Center in Hanover, New Hampshire. He was also a United States Air Force Major and Chief of Neurology of the United States Air Force Hospital in Wiesbaden, Germany.

Dr. Saelices earned her B.S. in biology and her Ph.D. in biochemistry from the University of Seville, where her training focused on molecular biology and structural biology. She performed postdoctoral research at ETH Zürich and UCLA, and was an Assistant and Associate Project Scientist at UCLA, where she focused on protein aggregation to develop new potential therapeutic strategies for transthyretin amyloidosis and Alzheimer's disease. She joined the UTSW faculty in 2020. Her lab applies crystallography and cryo-electron microscopy to obtain atomic information of amyloid structures, which is later used to design tools for the clinic. The lab's attention is mainly directed on transthyretin amyloidosis and Alzheimer’s disease.

Montreal Neurological Institute, McGill University, Montréal, QC, Canada Department of Human Genetics, McGill University, Montréal, QC, Canada

Dr. Salloway received his MD from Stanford Medical School and completed residencies in neurology and psychiatry at Yale University. He is the Martin M. Zucker Professor of Psychiatry and Human Behavior, and Professor of Neurology at the Warren Alpert Medical School of Brown University, and Chief of Neurology and Director of the Memory and Aging Program at Butler Hospital. Dr. Salloway is an internationally recognized leader in clinical trials for the prevention and treatment of Alzheimer’s disease. His program has conducted more than 100 clinical trials for Alzheimer’s and related disorders. He has chaired the Steering Committees for major AD pivotal trials and he has been a lead author for key publications in Alzheimer’s research in the New England Journal of Medicine, Nature and other top-tiered journals that have helped shaped the field of Alzheimer’s research. He also serves on the steering committees for major biomarker and clinical trials and consortia such as ADNI, DIAN, ACTC, GAP-NET and LEADS and he is a Project Arm Leader for the DIAN-TU study. Dr. Salloway has had a distinguished teaching career mentoring young investigators for careers in Alzheimer’s research. He has received numerous teaching awards at Brown and he helped establish Brown’s combined residency in neurology and psychiatry and the NIH-funded Dementia Research Fellowship. He is the Past President of the American Neuropsychiatric Association, a Fellow of the American Academy of Neurology and a member of the American Neurological Association. He serves as a consultant for drug development to the NIH, the Alzheimer’s Association, the Alzheimer’s Disease Drug Discovery Foundation and many other groups working on Alzheimer’s therapeutics. He has published more than 400 scientific articles and abstracts and edited 3 books and he lectures widely about the early diagnosis and prevention of Alzheimer’s disease. In May 2019 he was elected to the Rhode Island Heritage Hall of Fame for his work on Alzheimer’s research.

Head of the scientific Program, leading the research and development programs for ALS, Parkinson's disease, and Alzheimer's disease at NeuroSense Therapeutics, a clinical-stage biotech company developing novel treatments for ALS, as well as other neurodegenerative diseases. Neurobiologist with over 10 years of experience focusing on neurodegenerative diseases utilizing multidisciplinary methods. (co)Author of numerous publications in leading journals. Awards winner of multiple prizes and scholarships for academic achievement. Member of the BIO committee, member of "Bashaar" - an academic community for society in Israel, and member of "Midaat" -a non-profit organization for promoting public health. Ph.D. in Neurobiology from Tel Aviv University.

I am currently a post-doc researcher at Lund Univeristy (Sweden). My interests include Alzheimer's disease, especially fluid and neuroimaging biomarkers.

Dr. Maura Samarani received her Ph.D. in Biochemical Sciences from the University of Milan (Italy) where she studied the role of lysosomal dysfunction and plasma membrane sphingolipids in the onset of cell damage. Dr. Samarani is currently a postdoc in the Unit of Membrane Traffic and Pathogenesis headed by Prof. Chiara Zurzolo at the Institut Pasteur (Paris, France). In the Zurzolo group, Dr. Samarani aims to understand how lysosomes transferred between cells through Tunneling nanotubes (TNTs) contribute to the spreading of α-synuclein and to the neuronal damage in Parkinson’s disease. She is also interested in understanding the involvement of TNTs in the etiopathogenesis of Lysosomal Storage Disorders. Since she was a Ph.D. student, Dr. Samarani is involved in different outreach activities for adults and children (e.g., European Researchers’ Night, workshops in primary schools, collaboration with the association Native Scientist for pupils speaking Italian in Paris).

After a PhD in machine learning where I designed and developed, as part of a team, a software for neuroimaging studies enabling and encouraging reproducible science, and applied it to classification and early prediction of Alzheimer's disease, I joined Qynapse team to translate this knowledge into health care products having a direct impact on people's lives.

Jose V. Sanchez-Mut is a principal investigator at the Neuroscience Institute of Alicante, Spain. He received a B.S. in Biology from the University of Valencia (2005, Spain) and a PhD in Neurosciences from the Autonomous University of Barcelona (2014, Spain). He conducted his PhD training at the laboratory of Cancer Epigenetics lead by Prof. Manel Esteller at the Bellvitge Biomedical Research Institute (IDIBELL, Barcelona) and his postdoctoral training at the laboratory of Neuro-epigenetics headed by Prof. Gräff at the École Polytechnique Fédérale de Lausanne (EPFL, 2014-2020, Switzerland). From May 1st 2020, he is leading the laboratory of Functional Epi-Genomics of Aging and Alzheimer's Disease at the Neuroscience Institute of Alicante. His studies investigate the epigenetic underpinnings of brain function in physiological and pathological conditions. He has contributed to the recognition of the epigenetic specificity of different brain regions and cell types, highlighted circadian epigenetic alterations in neurodevelopmental syndromes, and identified genetic and epigenetic alterations in neurodegenerative diseases. His most recent studies investigate the contribution of the genetic-epigenetic interactions to the development of aging and Alzheimer’s disease alterations.

I'm a MSc Neuroscience student doing my internship at the Memory Unit of the Sant Pau Research Institute-Hospital de la Santa Creu i Sant Pau (Barcelona). My work focuses on unravelling synaptic pathology in AD and other dementias with super-resolution and biochemistry techniques.

Dr Sanderson is a researcher working at the interface of Chemistry and Biology, with particular expertise in the chemistry and biophysics of lipid membranes. He is a member of the British Biophysical Society (committee member), US Biophysical Society and the Royal Society of Chemistry (FRSC). Research in the Sanderson group focuses on the synthesis and chemical reactivity of lipids and the interactions of small organic molecules, proteins and peptides with membranes

Dr Cynthia Sandor (DVM,PhD) is a Sêr Cymru II Fellow and UK DRI Emerging Leader at the UK DRI at Cardiff. During her PhD at the University of Liège and first postdoctoral post at Harvard Medical School and the Broad Institute, Dr Sandor contributed to multiple genetics studies on auto-immune diseases such as Crohn’s disease and Rheumatoid arthritis. Next, while undertaking postdoctoral studies at the University of Oxford, she worked on evaluation of the validity of induced pluripotent stem cell derived neuronal models using bulk and single RNA sequencing experiments. This research contributed to the first single-cell human substantia nigra atlas - a brain region heavily impacted by Parkinson’s disease. Dr Sandor’s current research is aiming to elucidate the molecular mechanisms underlying disease severity and progression in Parkinson's disease, using a mainly computational strategy. Working with different data types and multiple clinical datasets, her team develop statistical/machine learning approaches to understand and predict the clinical presentation and progression of disease in people living with Parkinson’s.